<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030056</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-002016</org_study_id>
    <secondary_id>FD-R-002016-01</secondary_id>
    <nct_id>NCT00030056</nct_id>
  </id_info>
  <brief_title>GM-CSF in Patients With Pulmonary Alveolar Proteinosis</brief_title>
  <official_title>Trial of GM-CSF for Alveolar Proteinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to determine the efficacy and safety of granulocyte-macrophage&#xD;
      colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with&#xD;
      pulmonary alveolar proteinosis (PAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAP is a rare lung disease characterized by accumulation of surfactant phospholipids and&#xD;
      proteins within the lungs. There is no specific pharmacologic therapy for PAP and the current&#xD;
      practice of lung lavage under general anesthesia is invasive and has limitations. Although it&#xD;
      is unknown if the anti GM-CSF antibody is related to the disease pathogenesis, observations&#xD;
      suggest a role for GM-CSF in lung homeostasis as well as in the pathogenesis of PAP.&#xD;
&#xD;
      Patients will receive subcutaneous GM-CSF or placebo once a day and will be followed on an&#xD;
      outpatient basis at 2 weeks, and 1, 2, 3, 4, 5 and 6 months after initiation of therapy.&#xD;
      Clinical response will determine dosing schedule and will be evaluated by symptom scores, gas&#xD;
      exchange data, and chest radiographs.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>December 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of primary or idiopathic PAP&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  Liver enzymes no greater than 3 times normal&#xD;
&#xD;
          -  Women must use an effective method of contraception, be post menopausal, or be&#xD;
             surgically sterilized&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active respiratory infection&#xD;
&#xD;
          -  Active cardiovascular disease (e.g., cardiogenic pulmonary edema)&#xD;
&#xD;
          -  Underlying myeloproliferative disorder or leukemia&#xD;
&#xD;
          -  Other secondary cause of PAP (e.g., occupational exposure to silica or HIV with PCP)&#xD;
&#xD;
          -  At increased risk of side effects from GM-CSF therapy (i.e., rheumatoid arthritis,&#xD;
             immune thrombocytopenia, or autoimmune thyroiditis)&#xD;
&#xD;
          -  Previous therapy with GM-CSF&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Significant renal or liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Jewish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2002</verification_date>
  <study_first_submitted>January 30, 2002</study_first_submitted>
  <study_first_submitted_qc>January 30, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Sargramostim</keyword>
  <keyword>Injections, Subcutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

